Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...

Roche Holding (SWX:ROG) is back in focus after fresh attention on its TIGIT inhibitor research in cancer immunotherapy, ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Argobio Studio, the launch platform for Europe's best innovative science, today announced the successful seed financing of Enodia Therapeutics, a ...

CORA Loyalty, the loyalty portfolio arm of CORA Group ("CORA"), advises financial institutions to move beyond product-based rewards and adopt enterprise loyalty strategies that recognize and reward ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

The company is consolidating its operations in Vadodara, with US headcount slashed by over 80 percent, labs reduced from four ...

Every year, millions of infants and children undergo surgery under general anesthesia in the world. Sevoflurane is a commonly used pediatric ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Detailed price information for Arcus Biosciences Inc (RCUS-N) from The Globe and Mail including charting and trades.

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...